MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells by Liu,  S. et al.
MicroRNA93 Regulates Proliferation and Differentiation
of Normal and Malignant Breast Stem Cells
Suling Liu1*, Shivani H. Patel1, Christophe Ginestier2, Ingrid Ibarra3, Rachel Martin-Trevino1,
Shoumin Bai1, Sean P. McDermott1, Li Shang1, Jia Ke1, Sing J. Ou1, Amber Heath1, Kevin J. Zhang1,
Hasan Korkaya1, Shawn G. Clouthier1, Emmanuelle Charafe-Jauffret2, Daniel Birnbaum2,
Gregory J. Hannon3, Max S. Wicha1*
1Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America, 2Centre de Recherche en
Cance´rologie de Marseille, Laboratoire d’Oncologie Mole´culaire, UMR891 Inserm/Institut Paoli-Calmettes, Universite´ de la Me´diterrane´e, Marseille, France, 3 Program in
Genetics and Bioinformatics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States of America
Abstract
MicroRNAs (miRNAs) play important roles in normal cellular differentiation and oncogenesis. microRNA93 (mir-93), a
member of the mir106b-25 cluster, located in intron 13 of the MCM7 gene, although frequently overexpressed in human
malignancies may also function as a tumor suppressor gene. Using a series of breast cancer cell lines representing different
stages of differentiation and mouse xenograft models, we demonstrate that mir-93 modulates the fate of breast cancer
stem cells (BCSCs) by regulating their proliferation and differentiation states. In ‘‘claudinlow’’ SUM159 cells, expression of mir-
93 induces Mesenchymal-Epithelial Transition (MET) associated with downregulation of TGFb signaling and downregulates
multiple stem cell regulatory genes, including JAK1, STAT3, AKT3, SOX4, EZH1, and HMGA2, resulting in cancer stem cell
(CSC) depletion. Enforced expression of mir-93 completely blocks tumor development in mammary fat pads and
development of metastases following intracardiac injection in mouse xenografts. The effect of mir-93 on the CSC population
is dependent on the cellular differentiation state, with mir-93 expression increasing the CSC population in MCF7 cells that
display a more differentiated ‘‘luminal’’ phenotype. mir-93 also regulates the proliferation and differentiation of normal
breast stem cells isolated from reduction mammoplasties. These studies demonstrate that miRNAs can regulate the states
and fates of normal and malignant mammary stem cells, findings which have important biological and clinical implications.
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Introduction
miRNAs serve vital functions in many of normal developmental
processes, as well as in carcinogenesis. A number of these miRNAs
have been shown to function as oncogenes with increased
expression in lung cancer, prostate cancer and colorectal cancer
[1,2,3,4,5,6,7,8]. In contrast, other miRNAs such as Let7 are
frequently downregulated in malignancies including breast cancer
and lung cancer in these contexts functioning as a tumor
suppressor gene [9,10,11]. The mir106b-25 cluster is composed
of the highly conserved miRNA106b (mir-106b), miRNA93 (mir-
93) and miRNA25 (mir-25) that have been reported to be
overexpressed in a number of cancers including gastric, prostate
and pancreatic neural endocrine tumors, neuroblastoma and
multiple myeloma [1,2,3]. These miRNAs are located in a 515-
base region on chromosome band 7q22 in intron13 of the host
MCM7 gene where they are co-transcribed in the context of
MCM7 primary transcripts [1]. MCM7 is a DNA licensing factor
obligate for cellular replication. Studies have suggested that the
mir-106b-25 miRNA cluster functions as a proto oncogene.
Several studies suggest that a primary mechanism of oncogenesis
involves targeting of PTEN which cooperates with MCM7 to drive
cellular proliferation [12]. Despite evidence for this miRNA cluster
functioning as a proto oncogene, in some contexts it has been
reported to function as a tumor suppressor inhibiting tumor
growth [13]. The molecular mechanisms accounting for this
discrepancy have not been determined.
Studies associating miRNA expression with oncogenesis have
largely been performed in bulk tumor populations. However, there
is substantial evidence supporting the CSC hypothesis which
suggests that tumors are hierarchically organized and that many
tumors, including those of the breast, are maintained by a
subpopulation of cells that displays stem cell properties [14,15,16].
These cells may mediate invasion and metastasis and contribute to
treatment resistance [17]. miRNAs have also been found to play
important roles in normal and malignant stem cell function. Silber
et al, reported that mir-124 and mir-137 induced differentiation of
neural and glioblastoma stem cells, a state associated with cell
cycle arrest [18]. Furthermore, recent studies have shown that the
miRNAs Let7 and mir-200c regulate self-renewal of BCSCs
[10,19]. Stem cell regulatory genes such as BMI-1 and HMGA2
may mediate this process [10,19]. We have previously demon-
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strated that normal breast tissue, primary breast cancers and
breast cancer cell lines contain subpopulations with stem cell
properties that can be enriched by virtue of their expression of
aldehyde dehydrogenase (ALDH) as assessed by the Aldefluor
assay (Stem Cell Technologies, Inc., Vancouver, British Columbia)
or by tumor initiation in NOD/SCID mice [20]. Recently, Ibarra,
et al, showed that Let7, as well as mir-93 are highly depleted in
mouse mammary stem/progenitor cells isolated with the stem cell
marker ALDH [21]. We have utilized breast cancer cell lines
representing different molecular subtypes of breast cancer as well
as primary xenografts of breast cancer and normal mammary cells
to examine the role of mir-93 in the regulation of normal and
malignant breast stem cells. We demonstrate that this miRNA is
able to regulate stem cell fate including cellular proliferation and
differentiation. These studies suggest that miRNAs regulate the
transition between CSC states findings which have important
biological and clinical implications.
Results
Tumor initiating capacity is associated with low mir-93
expression
We have previously demonstrated that primary human breast
cancers and established breast cancer cell lines contain subpop-
ulations with stem cell properties that can be isolated by virtue of
their expression of ALDH as assessed by the Aldefluor assay.
These cells displayed increased tumor initiating capacity and
metastatic potential compared to corresponding Aldefluor-nega-
tive cells [22]. mir-93 was shown as one of the most abundant
miRNAs in ALDH2 cells [21]. As assessed by qRT-PCR, mir-93
expression was significantly increased in the ALDH2 compared to
ALDH+ populations in SUM159 claudinlow and HCC1954 basal
subtype of human breast cancer (Figure 1A and Figure S1A). As
shown in Figure S3, mir-93 expression was lower in CSCs which
were characterized by their expression of the CSC markers:
ALDH+ or CD242CD44+. To determine the relationship between
mir-93 expression and tumor initiating capacity, we constructed a
mir-93 sensor tagged with GFP (mir-93-sensor-GFP) containing a
mir-93 target UTR coupled to GFP. In cells transfected with this
vector, mir-93 expression results in degradation of GFP mRNA
(sensor-negative), whereas mir-93-negative cells express GFP
(sensor-positive) (Figure 1B). mir-93 expression was significantly
higher in GFP-negative cells than GFP-positive cells (Figure S4)
and the ALDH1A1 was much lower in GFP-negative cells than
GFP-positive cells as accessed by western blot or immunohisto-
chemical staining (Figure S5). Furthermore, GFP was significantly
reduced by overexpression of mir-93 (Figure S6), demonstrating
that the sensor reports mir-93 function. The relationship between
mir-93 expression and tumor initiation was determined by
introducing serial dilutions of sensor-positive (mir-93-negative)
and sensor-negative (mir-93-positive) SUM159 cells into the
mammary fatpads of NOD/SCID mice. As shown in Figure 1C,
sensor-positive (mir-93-negative) cells had significantly higher
tumor initiating capacity and CSC frequency than sensor-negative
(mir-93-positive) cells. Moreover, mir-93-negative cells gave rise to
tumors containing both mir-93-negative and mir-93-positive
populations, whereas mir-93-positive cells gave rise only to small,
slow growing tumors containing exclusively mir-93-positive
populations (Figure 1D). Similar findings were seen using
HCC1954 cells (data not shown). These studies demonstrated
that in these breast cancer cell lines low mir-93 expression is
associated with the CSC phenotype characterized by increased
aldehyde dehydrogenase expression, tumor initiating capacity and
the ability to generate heterogeneous tumors containing both stem
cell and non-stem cell populations.
mir-93 overexpression decreases CSCs in vitro
We utilized a tetracycline (TET) inducible mir-93 construct
tagged with RFP (pTRIPZ-mir-93-RFP) to determine the
functional role of mir-93 in CSCs. mir-93 levels were significantly
increased by ten hours following tetracycline induction in these
cells (Figure 2A). Induction of mir-93 was associated with a
significant decrease in the CSC population as assessed by the
Aldefluor assay (Figure 2B), which were also seen in two basal
breast cancer cell lines HCC1954 and SUM149 (Figure S1B and
Figure S7). Furthermore, this decrease did not result from
induction of apoptosis in these cells as assessed by Annexin V
staining (Figure 2B). Our group and others have previously shown
that CSCs were relatively resistant to cytotoxic chemotherapy.
Consistent with this, addition of the cytotoxic agent docetaxel
resulted in a relative increase in the percentage of Aldefluor-
positive cells (Figure 2B), an increase associated with induction of
apoptosis in the bulk cell population (42.8% versus 1.1% control)
(Figure 2B). The relative increase in the Aldefluor-positive
population seen with docetaxel treatment was abrogated by
simultaneous mir-93 expression (Figure 2B). These experiments
suggested that unlike cytotoxic agents which primarily target the
bulk cell population, mir-93 overexpression was able to reduce the
CSC population. Moreover, this did not appear to result from
increased CSC apoptosis suggesting a potential role for mir-93 in
promoting differentiation of CSCs. Furthermore, since the TET-
inducible mir-93 system allows for the controlled regulation of
CSC populations, it provides a valuable tool for assessing the role
of CSCs in tumor growth in mouse xenograft models. Further-
more, the ability to regulate the CSC population during different
phases of tumor growth allows for the assessment of the role of
these cells in tumor initiation and maintenance.
Author Summary
Recent evidence suggests that many cancers, including
those of the breast, are maintained by a population of
cancer cells that display stem cell properties. These ‘‘cancer
stem cells’’ may also contribute to tumor metastasis,
treatment resistance, and relapse. Recently, miRNAs (small
non-coding RNAs) have been reported to be capable of
functioning as oncogenes or tumor suppressors. miRNA93
(mir-93) is frequently overexpressed in human cancer but,
paradoxically, has been found to function as a tumor
suppressor in some contexts. Using a series of breast
cancer cell lines representing different stages of differen-
tiation and mouse xenograft models, we demonstrate that
mir-93 modulates the fate of breast cancer stem cells by
regulating their proliferation and differentiation states. In
less differentiated tumors, enforced expression of mir-93
completely blocks tumor development in mammary fat
pads and development of metastases following intracar-
diac injection in mouse xenografts by reducing breast
cancer stem cells. However, the effect of mir-93 on the
cancer stem cell population is dependent on the cellular
differentiation state, with mir-93 expression increasing the
cancer stem cell population in more differentiated breast
tumors. These studies demonstrate that miRNAs can
regulate breast stem cell proliferation and differentiation,
an observation with important biological and clinical
implications.
mir-93 Regulates Breast Stem Cells
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mir-93 overexpression inhibits the growth of established
tumor xenografts
We first determined the effect of mir-93 induction on the growth
of established tumors and compared these effects to those of
cytotoxic chemotherapy. When tumors reached 0.2–0.3 cm in
diameter, we induced mir-93 (with doxycycline treatment,
hereafter DOX) or initiated cytotoxic chemotherapy with
docetaxel or the combination. Induction of mir-93 significantly
inhibited the growth of SUM159 and HCC1954 xenografts
(Figure 2C and Figure S1C). Furthermore, induction of mir-93
further reduced tumor growth when added to the docetaxel
chemotherapy (Figure 2C and Figure S1C). Following five weeks
of treatment, animals were sacrificed and CSC populations were
assessed by the Aldefluor assay and ALDH1 immunohistochem-
istry. Induction of mir-93 alone or in combination with docetaxel
reduced the Aldefluor-positive population by more than 60%
compared to control or docetaxel alone (Figure 2D and Figure
S1D). These observations were confirmed by immunohistochem-
istry of ALDH1 expression (Figure 2D and Figure S1D). mir-93
expression was significantly higher in DOX group compared to
the control group at the end of treatment (Figure S2). To provide a
more definitive assessment of CSCs, we determined the ability of
serial dilutions of cells obtained from primary tumors to form
tumors in secondary NOD/SCID mice. Tumor cells isolated from
docetaxel treated mice, initiated tumors at lower concentrations
with accelerated growth compared to control animals (Figure 2E,
Figure S1E). This was consistent with previous studies demon-
strating a relative increase in CSCs following chemotherapy [17].
In contrast, cells isolated from tumors with mir-93 induction with
or without docetaxel chemotherapy had markedly reduced tumor
initiating capacity in secondary mice with no tumors observed
from introduction of fifty cells from the mir-93 docetaxel treated
group (Figure 2E, Figure S1E). The CSC frequency was lower in
the groups of DOX alone and DOX+docetaxel, and was
significantly increased in the docetaxel group (Figure 2E and
Figure S1E). These studies demonstrated that mir-93 induction
reduced the CSC population reducing growth of established tumor
xenografts.
In order to determine whether down-regulation of mir-93
promoted tumorigenesis, we utilized a mirZip anti-sense miRNA
in SUM159 cells. qRT-PCR was utilized to confirm the efficient
knock-down of mir-93 (Figure S8A). ALDH+ cells were signifi-
cantly increased after mir-93 was knocked down (mirZip93-
DsRed) (Figure S8B). As shown in Figure S8C, knockdown of mir-
93 significantly promoted the growth of SUM159 cells in tumor
xenografts and increased the CSC frequency. Furthermore, the
proportion of ALDH+ cells were significantly increased after mir-
93 was knocked down (mirZip93-DsRed) (Figure S8D).
mir-93 expression in the adjuvant setting prevents tumor
growth
Preclinical models have suggested that CSCs play a role in
tumor recurrence and metastasis following adjuvant therapy [23].
This suggests that targeting of CSCs may have more dramatic
effects in the adjuvant than in the advanced tumor settings. To
simulate the adjuvant setting we induced mir-93 and/or admin-
istered docetaxel immediately after tumor cell implantation.
Although tumors grew after four to five weeks in control animals,
there was no observed tumor growth following mir-93 induction
and/or docetaxel treatments for eight weeks (Figure 2F, Figure
S1F). After eight weeks, treatments were stopped and animals
observed for an additional ten weeks. In SUM159 xenografts,
tumors developed in all mice who received eight weeks of
docetaxel alone. In contrast, no tumors developed in mice
Figure 1. mir-93-negative SUM159 cells have increased tumor-initiating capacity. A. ALDH+ cells from SUM159 cells shows lower mir-93
expression level in comparison to ALDH2 cells as accessed by qRT-PCR. P,0.05; Error bars represent mean6 STDEV. B. A schematic of mir-93-Sensor-
GFP lentiviral construct; C. SUM159 cells were transduced with the mir-93-sensor-GFP lentivirus and selected with hygromycin B, and cells were
sorted based on the GFP expression. A serial dilution of mir-93-negative (sensor/GFP-positive) SUM159 cells and mir-93-positive (sensor/GFP-
negative) SUM159 cells were injected into the 4th fatpads of NOD/SCID mouse. *p,0.05. D. mir-93-negative cells gave rise to tumors containing both
mir-93-negative and mir-93-positive cell populations, but mir-93-positive cells only gave rise to tumors containing mir-93-positive cell populations.
doi:10.1371/journal.pgen.1002751.g001
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following mir-93 induction with or without docetaxel (Figure 2F,
Figure S1F). In order to extend these observations to primary
breast tumors, we examined the effect of mir-93 induction on three
primary breast xenografts, MC1 (Figure S10A), UM2 (Figure
S10B) and UM1 (Figure S10C) which were directly established
from patient tumors and not passaged in vitro. MC1 and UM1
were derived from claudinlow and UM2 from a basal breast
carcinoma. Induction of mir-93 upon cell implantation completely
Figure 2. mir-93 inhibits tumor growth and metastasis by decreasing CSCs in SUM159 cells. A. SUM159 cells were transduced with the
pTRIPZ-mir-93 lentivirus and selected with Puromycin for 7 days. Tetracycline (DOX) induces mir-93 expression in suspension-cultured SUM159 cells
by 10 hours; B. 16106 SUM159 cells or pTRIPZ-SUM159 -mir-93 cells were plated in T75 flasks and, after overnight, the cells were treated with Vehicle
control, with (DOX) or without (CTRL) DOX (1 ug/ml), docetaxel (10 nM) or the combination for 7 days. Cells were utilized for Aldefluor assay and
stained for Annexin V-APC and DAPI for apoptosis assay. C. 100 k pTRIPZ-SUM159-mir-93 cells were injected into the 4th fatpads of NOD/SCID mice.
The treatment started as indicated by the red arrow. DOX alone (1 mg/ml in drinking water), or docetaxel (10 mg/kg i.p. once weekly) alone, or the
combination inhibits SUM159 tumor growth in vivo (note: The Y-axis is on a logarithmic scale). D. Tumors from each group were collected. ALDH was
accessed by the Aldefluor assay on viable dissociated cells and by ALDH1 immunohistochemistry on fixed sections. E. Serial dilutions of cells obtained
from these xenografts were implanted in the 4th fatpads of secondary mice, which received no further treatment. F. 10k pTRIPZ-SUM159-mir-93 cells
were injected into the 4th fatpads of NOD/SCID mice. The treatment started immediately after injection as indicated by the red arrow and stopped as
indicated by the green arrow. G. 200k pTRIPZ-SUM159-mir-93-Luc cells in 100 ul of PBS were injected into the left ventricle of NOD/SCID mice. The
treatment started immediately after injection as indicated by the red arrow and stopped as indicated by the green arrow. Metastasis formation was
monitored using bioluminescence imaging. Quantification of the normalized photon flux, measured at weekly intervals following inoculation.
*p,0.05; Error bars represent mean6 STDEV. The colored ‘‘*’’ on the side of the tumor growth curve indicates that the tumor growth or metastasis is
significantly different between the control group and the group with the same colored curve.
doi:10.1371/journal.pgen.1002751.g002
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prevented tumor growth in this model. Together these studies
suggested that mir-93 regulated the CSC population and that this
population mediates tumor growth following adjuvant therapy.
mir-93 prevents tumor metastasis in the adjuvant setting
Previous studies have demonstrated that CSCs mediate tumor
invasion and metastasis. To determine the effect of mir-93
expression on tumor invasion, we examined the effect of mir-93
induction and/or downregulation on invasion of SUM159 cells
using a matrigel invasion assay. Overexpression of mir-93
significantly inhibited the ability of SUM159 cells to invade in
this assay (Figure S8E). In contrast, knockdown of mir-93 utilizing
the mirZip93-DsRed promoted tumor invasion (Figure S8F).
To determine whether the expression of mir-93 affect the
growth of tumor metastasis in vivo, SUM159 (Figure 2G) and
HCC1954 (Figure S1G) cells co-transfected with the inducible
mir-93 vector and luciferase were introduced into NOD/SCID
mice by intracardiac injection and metastasis formation monitored
by bioluminescence imaging. DOX and/or docetaxel treatments
were initiated following intracardiac injection. As shown in
Figure 2G, mir-93 induction completely suppressed whereas
docetaxel partially suppressed metastasis formation. Metastasis
was confirmed by histologic examination with pan-cytokeratin
staining (Figures S9, S1H). Treatments were stopped at eight
weeks and animals were observed for an additional ten weeks for
development of metastasis. In animals receiving docetaxel alone,
metastasis rapidly developed following cessation of therapy. In
contrast, no metastases developed in mice following mir-93
induction with or without docetaxel chemotherapy (Figure 2G).
In animals injected with HCC1954 cells, animals from all groups
developed metastasis following cessation of therapy. However,
development of metastasis were delayed and reduced in mice
following mir-93 induction with or without docetaxel chemother-
apy (Figure S1G).
mir-93 overexpression increases the CSC population and
accelerates tumor growth in luminal subtype MCF7 cells
Human breast cancer represents a heterogeneous set of diseases
with distinct molecular profiles and clinical behaviors [24]. These
subtypes may represent different cells of origin and/or differen-
tiation state. It has been proposed that the most undifferentiated
‘‘claudinlow’’ tumors originate from and resemble normal mam-
mary stem cells, whereas the triple-negative basal tumors arise
from a more differentiated luminal progenitor cell and the most
differentiated luminal tumors which express estrogen and proges-
terone receptors originate from and are composed of the most
differentiated cells [24]. To determine the relationship between
mir-93 expression and level of cellular differentiation, we
compared the expression of mir-93 in claudinlow (SUM159), basal
(HCC1954) and luminal (MCF7) cells. As shown in Figure S11,
mir-93 levels correlate with postulated differentiation state of these
cell lines. Furthermore, in the claudinlow SUM159 cells and basal
HCC1954 cells, mir-93 expression is significantly lower in
Aldefluor-positive as compared to Aldefluor-negative populations
(Figure S11). In contrast, the CSC population in MCF7 cells
characterized by the phenotype CD242CD44+ [25] expressed the
same high level of mir-93 as did the other (non-stem) cells
constituting the bulk population (Figure 3A, Figure S11). This
suggests that mir-93 may play a different role in more
differentiated luminal breast cancer than in the more undifferen-
tiated claudinlow and basal subtype. Consistent with this, induction
of mir-93 in MCF7 cells increased the CD242CD44+ population
(Figure 3B). Docetaxel also increased this population, as did the
combination of mir-93 plus docetaxel (Figure 3B). In xenografts,
induction of mir-93 accelerated the growth of MCF7 xenografts
compared to control (Figure 3C), findings which were confirmed
using two additional luminal cell lines MDA-MB-453 and T47D
(Figures S12A and S13A). In contrast, docetaxel reduced tumor
growth (Figure 3C). Analysis of treated MCF7 tumors confirmed
that mir-93 induction increased the proportion of CD242CD44+
cells and ALDH+ cells in tumors as did docetaxel or DOX plus
docetaxel (Figure 3D). mir-93 expression level was significantly
higher in DOX group compared to the control group at the end of
treatment (Figure S14). mir-93 induction increased the proportion
of ALDH+ cells from 1.01% to 9.5% in MDA-MB-453 tumors
(Figure S12B) and from 1.26% to 3.84% in T47D tumors (Figure
S13B). Furthermore, the calculated tumor initiating frequency was
significantly increased after mir-93 induction (Figure 3E, Figures
S12C and S13C). These results were confirmed and extended by
demonstrating that mir-93 induction in primary tumors increased
their tumor-initiating capacity when implanted into secondary
recipients (Figure 3E, Figures S12C, S13C). Together, these
experiments suggested that the effects of mir-93 on the CSC
population differed in different molecular subtypes of breast
cancer, an observation consistent with the hypothesis that miRNA
effects might be differentiation state dependent.
mir-93 downregulates stem cell regulatory genes in
BCSCs
In order to determine the cellular targets of mir-93 in BCSCs,
ALDH+ and ALDH2 populations of SUM159 cells were
separated and cultured in suspension in the presence or absence
of DOX for ten hours. Gene expression profiles in the four
populations were determined utilizing Affymetrix oligonucleotide
microarrays (Figure 4A). Of the 2,000 genes downregulated at
least two-fold upon DOX treatment in the ALDH+ population
(Table S1), 127 overlapped with the predicted target sequences of
mir-93 including twenty-four genes known to be involved in stem
cell regulation (Figure 4A and Table S2) including JAK1, SOX4,
STAT3, AKT, E2H1 and HMGAZ. The downregulation of these
genes in pTRIPZ-SUM159-mir-93, pTRIPZ-HCC1954-mir-93
cell lines and pTRIPZ-MC1-mir-93 were confirmed with custom-
ized PCR array plates (Figures S15, S16, S17). In contrast, only
352 genes were significantly downregulated by DOX in the
ALDH2 population (Table S3) with twelve of these genes (no stem
cell genes) overlapping with the predicted mir-93 targets. These
studies suggest that mir-93 regulates the CSC population by
simultaneously targeting a number of stem cell regulatory genes.
To confirm this, we utilized a luceriferase reporter assay to
determine the effect of mir-93 on the expression of the stem cell
regulatory genes AKT3, SOX4 and STAT3 selected from the
expression profiling data. Expression of mir-93 reduced the level of
these stem cell regulatory genes in SUM159 (Figure 4B) and
HCC1954 cells (Figure S18) but not in luminal MCF7 and MDA-
MB-453 cells (Figure S19). Furthermore, knockdown of STAT3 or
SOX4 but not AKT3 decreases the proportion of ALDH+
SUM159 cells suggesting these genes play a role in the regulation
of CSC self-renewal (Figure S20). The 127 genes in pTRIPZ-
MCF7-mir-93 were also tested with customized PCR array plates,
and interestingly, most of the stem cell genes were not knocked-
down by mir-93 induction in the ALDH+ proportion of MCF7
(Figure S21).
mir-93 regulates cell proliferation
To determine the relationship between mir-93 expression and
cell cycle kinetics, we assessed mir-93 expression in quiescent and
cycling ALDH+ and ALDH2 populations. Cycling (S/G2/M) cells
expressed significantly higher levels of mir-93 compared to
mir-93 Regulates Breast Stem Cells
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quiescent (G0/G1) cells in both the ALDH2 and ALDH+
compartments (Figure 5A). To determine whether mir-93 induces
or is a consequence of cellular proliferation, we utilized the DOX
inducible mir-93 construct to determine the effect of mir-93
induction on cell cycle distribution. Induction of mir-93 reduced
the quiescent cell population from 64% to 42% suggesting that this
miRNA has the capacity to directly regulate the cell cycle
(Figure 5B). Furthermore, induction of mir-93 increased the
proliferation of SUM159 by 29% (Figure S22). Although mir-93
induction had similar effects on the basal HCC1954 cell lines it
had no significant effect on the cell cycle of the luminal MCF7 cells
(Figure S22, Figure S23).
To determine the relationship between the stem cell phenotype
and cell cycle kinetics, we determined the cell cycle distribution of
ALDH+ and ALDH2 populations. The ALDH+ population in
SUM159 cells had a higher fraction of non-cycling cells compared
to ALDH2 cells (Figure 5A). This finding was confirmed by Ki67
and MCM7 staining (Figure S24).
mir-93 promotes Mesenchymal-Epithelial Transition
(MET) in SUM159 cells
SUM159 cells are derived from a ‘‘claudinlow’’ subtype of breast
cancer which is characterized as having a high proportion of cells
displaying ‘‘epithelial-mesenchymal transition (EMT)’’. This state
is characterized by loss of epithelial characteristics such as apical
basal polarity and E-Cadherin expression and acquisition of
mesenchymal characteristics, including loss of cell polarity and
expression of Vimentin. We determined the effects of mir-93
expression on MET of SUM159 cells by assessing markers of these
states at the protein and mRNA levels. SUM159 cells have a
mesenchymal morphology and express Vimentin, but not the
epithelial marker E-Cadherin, an effect not dependent on cell
density (Figure 6A). Expression of mir-93 in these cells caused
them to assume a more epithelial appearance associated with a
decrease in Vimentin and an increase in E-Cadherin expression
(Figure 6A). Similar effects were seen in the basal HCC1954 cell
line (Figure S25) although these were less pronounced. To confirm
and extend these results we determined the effect of mir-93
expression on mRNA expression of a wider panel of epithelial and
mesenchymal markers. We also determined the time course of
expression of epithelial and mesenchymal marker mRNAs
expressed in ALDH+ stem cells and ALDH2 non-stem cell
populations. Expression of mir-93 in SUM159 cells resulted in a
time dependent decrease in expression of mesenchymal markers,
Vimentin, N-cadherin and Twist, and an increase in the epithelial
markers E-Cadherin and Claudin (Figure 6B). Furthermore,
Figure 3. mir-93 promotes tumor growth by increasing CSCs in MCF7 cells. A. Mir-93 is expressed equally in CD242CD44+ and bulk (non-
CD242CD44+) populations of MCF7 cells. B. 16106 pTRIPZ-MCF7-mir-93 cells were plated in T75 flasks and, after overnight, the cells were treated with
Vehicle control, DOX (1 ug/ml), docetaxel (10 nM) or the combination for 7 days. DOX alone, docetaxel alone or the combination increased the
CD242CD44+ population in vitro. C. 1000k pTRIPZ-MCF7-mir-93 cells were injected into the 4th fatpads of NOD/SCID mice. Treatment was initiated as
indicated by the red arrow. DOX alone (1 mg/ml in drinking water) promoted MCF7 tumor growth in vivo; docetaxel (10 mg/kg i.p. once weekly)
alone or the combination inhibits MCF7 tumor growth in vivo. D. Tumors from each group were collected. Analysis for CD24 and CD44 was
performed on dissociated cells. DOX alone, docetaxel alone, or the combination increased the CD242CD44+ populations in MCF7. E. Serial dilutions of
cells obtained from these xenografts were implanted in the 4th fatpads of secondary mice, which received no further treatment. Cells from DOX-,
docetaxel-, or combination-treated tumors formed secondary tumors at all dilutions (50000, 5000, 500), whereas only higher numbers of cells (50000,
5000) obtained from control xenografts were able to generate tumors. *p,0.05; Error bars represent mean 6 STDEV. The colored ‘‘*’’ on the side of
the tumor growth curve indicates that tumor growth is significantly different between the control group and the group with the same colored curve.
doi:10.1371/journal.pgen.1002751.g003
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although these effects were seen in ALDH2 populations, they were
even more pronounced in the ALDH+ stem cell compartment.
Since TGFb is a major inducer of the EMT [26,27], we examined
the effect of mir-93 expression on components of this pathway.
Interestingly, expression of mir-93 significantly reduced expression
of the mRNA for TGFbR2 in both ALDH+ and ALDH2
SUM159 cells. This effect was seen as early as twelve hours,
suggesting a potential role for down regulation of TGFb signaling
in inducing the MET.
mir-93 maintains normal breast stem cells in an epithelial
state
In addition to breast cancer cells, we also determined the effects
of mir-93 expression on normal breast cell differentiation. We
utilized flow cytometry to access expression of EpCAM and
CD49f in breast epithelial cells obtained from reduction mam-
moplasties. It has previously been shown that mammary stem cells
are contained within the EpCAM2CD49f+ population while
double positive (EpCAM+CD49f+) cells are luminal progenitors,
EpCAM+CD49f2 more differentiated Luminal cells, while
EpCAM2CD49f2 constitute stromal cells [28]. We compared
mir-93 expression levels in these four populations. Interestingly,
we found that the highest level of mir-93 is expressed in the
EpCAM+CD49f+ population (Figure 7A), which suggested mir-93
was required to maintain the cells as EpCAM+CD49f+. Further-
more, overexpression of mir-93 in freshly isolated normal breast
cells or in immortalized non-transformed MCF-10A cells in-
creased the proportion of cells expressing EpCAM (Figure 7B,
7C). These studies suggested that mir-93 played a role in
maintaining normal breast cells in an epithelial (EpCAM+) state.
Discussion
In these studies, we demonstrate that mir-93 is capable of
modulating breast CSC populations by regulating their prolifer-
ation and differentiation states. To examine this, we utilized breast
cancer cell lines representing different states of differentiation. The
levels of endogenous mir-93 expression paralleled cellular differ-
entiation states with mir-93 levels lowest in the most primitive
‘‘claudinlow’’ SUM159 cells, highest in the ‘‘luminal’’ MCF7 cells
and intermediate in the ‘‘basal’’ HCC1915 cells. We utilized a
DOX inducible system to determine the effects of enforced mir-93
expression on the CSC populations assessed by expression of the
stem cell markers ALDH and CD242CD44+ as well as by mouse
xenograft assays [14,22]. Enforced mir-93 expression in claudinlow
and basal breast cancer cell lines significantly reduced the CSC
populations as assessed by the Aldefluor assay. To assess the
functional relevance of this, we determined the effect of mir-93
induction in SUM159 and HCC1954 cells on tumor growth in
NOD/SCID mouse xenografts. The effects of mir-93 expression
on tumor initiating capacity was confirmed using two primary
breast xenografts generated without in vitro culture. mir-93
expression decreased the CSC in these claudinlow primary
xenografts. In contrast, overexpresson of mir-93 in the luminal
MCF7 cells line resulted in an increase in CD242CD44+ CSC
resulting in increased tumor growth. This demonstrates that the
effect of mir-93 on CSC populations is dependent on the cellular
differentiation state. This model allowed us to simulate potential
clinical scenarios involving CSC targeting agents. To simulate the
effects of CSC targeting agents in advanced disease, tumors were
inoculated into mammary fatpads and when the tumors were
palpable mir-93 was induced by addition of doxycycline to the
mouse drinking water. In this setting, mir-93 induction had only a
modest effect in reducing tumor growth. Addition of the
chemotherapeutic agent docetaxel resulted in a more significant
reduction in tumor size, an effect that was accentuated by mir-93
induction. CSC models predict that the efficacy of CSC targeting
agents should be most pronounced in the adjuvant setting where
tumor growth from micrometastasis is dependent on stem cell self-
renewal [29]. Consistent with this model, induction of mir-93
immediately after fatpad implantation or after development of
micrometastasis by intracardiac injection completely blocked
tumor recurrence. Furthermore, when treatment was discontinued
at eight weeks, animals that received chemotherapy alone
Figure 4. mir-93 targets stem cell regulatory genes. A. Schematic
representation of the experimental design to identify the direct targets
of mir-93 in SUM159 cells. B. Activity of the luciferase gene linked to the
39UTR of AKT3, SOX4, or STAT3. The pMIR-REPORT firefly luciferase
reporter plasmids with the wild-type 39UTR sequences of AKT3, SOX4,
or STAT3 were transiently transfected into pTRIPZ-mir-93-SUM159 cells
and an internal control ACTB luciferase reporter was co-transfected for
normalization. The cells were treated with or without DOX. Luciferase
activities were measured after 48 hr. The relative luciferase activity was
calculated as the ratio of (the results from the cells transfected by
individual reporter)/(the results from the cells transfected by the
internal control in the same cell group). The data are mean and
standard deviation (SD) of separate transfections (n = 4). *p,0.05; Error
bars represent mean 6 STDEV.
doi:10.1371/journal.pgen.1002751.g004
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developed local tumor growth and metastasis while those with mir-
93 induction with or without chemotherapy showed no recurrence
when animals were sacrificed after four months. These studies
provide strong support for the CSC hypothesis and provide a
valuable animal model for clinical trial design using CSC targeting
agents.
To determine the molecular mechanisms of mir-93 CSC
regulation, we employed an unbiased approach assessing the
effect of mir-93 expression on early changes in global gene
expression profile coupled with prediction of miRNA target
sequences. Interestingly, this analysis revealed that twenty-four
genes known to be involved in stem cell self-renewal including
JAK1, SOX4, STAT3, AKT, EZH1, HMGA2 are targeted by
mir-93. In addition, this miRNA targets two important regulators
of TGFb signaling, TGFbR2 and SMAD5.
mir-93 expression was also associated with and in turn regulates
cellular proliferation. Quiescent G0/G1 cells expressed lower
levels of mir-93 than proliferating cells in S/G2/M phase.
Furthermore, enforced expression of mir-93 increased the fraction
of cycling cells.
We demonstrate that induction of mir-93 in mesenchymal-like
SUM159 cells induces an MET in the ALDH+ CSC population
characterized by increased expression of E-Cadherin and Claudin,
with concomitant downreguation of mesenchymal genes, such as
Vimentin, N-Cadherin and Twist. mir-93 also inhibits TGFb
signaling by targeting TGFbR2, an effect seen within twelve hours
of mir-93 induction. This was followed by an MET in the
Aldefluor-positive CSC population. Since TGFb is a major
regulator of EMT, abrogation of this signaling pathway may
facilitate MET. Of interest, it has been recently reported that the
mir-106b-25 cluster including mir-93 is induced in the early stages
of nuclear reprogramming of fibroblasts into IPS cells [30]. This is
accompanied by a mesenchymal to epithelial conversion in these
cells which is obligatory for reprogramming to recur. This suggests
that this miRNA cluster may regulate MET in multiple biological
contexts.
In summary, our experiments suggest that CSCs can exist in
two alternative epithelial and mesenchymal states, the balance of
which is regulated by miRNAs including mir-93 (Figure 8). The
mesenchymal state associated with an invasive phenotype charac-
terized by quiescence and low mir-93 expression is maintained by
growth factors such as TGFb. Upon activation of cellular
proliferation, MYC and E2F are induced leading to expression
of MCM7, a licensing factor required for DNA synthesis.
Concomitantly, mir-93 and its related miRNA cluster is co-
synthesized which promotes further proliferation while simulta-
neously downregulating TGFb signaling. This facilitates a
mesenchymal to epithelial transition in the CSC population
characterized by decreased invasiveness and increased prolifera-
tion. Continued expression of mir-93 simultaneously downregu-
lates a number of stem cell self-renewal pathways including JAK/
STAT, AKT, EZH1 and HMGH2, promoting cellular differen-
tiation and depleting the CSC population. The model depicted in
Figure 8 is consistent with our observation that mir-93 level is
highest in the EpCAM+CD49f+ normal mammary cells and
decreased with terminal differentiation. In contrast, the effects of
mir-93 depend on the cellular differentiation state accounting for
differences we observed in claudinlow, basal and luminal breast
cancers, with mir-93 level highest in the luminal MCF7 cell line
compared to basal HCC1954 and claudinlow SUM159 cell lines.
MCF7 cells are highly proliferative although unlike normal
mammary cells incapable of terminal differentiation (Figure 8).
Figure 5. mir-93 regulates the cell cycle in SUM159 cells. A. SUM159 cells were stained with Aldefluor and Hoechst33342 and dead cells
excluded by 7-AAD staining. Cells from G0/G1 and S/G2/M were sorted from ALDH+ or ALDH2 populations and mir-93 expression was measured with
qRT-PCR. B. Cell cycle analysis of pTRIPZ-SUM159-mir-93 cells in the presence or absence of DOX for 7 days. Propidium iodide staining followed by
flow cytometry was used to analyze cell cycle distribution. mir-93 induction with DOX resulted in a decreased proportion of cells in G0/G1 and an
increased proportion of cells in S/G2/M. *p,0.05; Error bars represent mean 6 STDEV.
doi:10.1371/journal.pgen.1002751.g005
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Figure 6. mir-93 initiates MET in SUM159 cells. A. pTRIPZ-SUM159-mir-93 cells were plated in 2-well chamber slides with (DOX) or without
(CTRL) Doxycycline for 7 days. E-Cadherin and Vimentin were deleted by immunofluorescence staining. Expression of mir-93 in SUM159 cells causes
them to assume a more epithelial appearance associated with a decrease in Vimentin and an increase in membrane localized E-Cadherin expression.
The phase micrographs for CTRL and DOX are also shown. E-Cadherin, Green; Vimentin, Red; DAPI, Blue. A representative sample from 3 independent
samples is shown. B. The effect of mir-93 expression on a panel of epithelial and mesenchymal markers at the mRNA level as accessed by qPCR.
pTRIPZ-SUM159-mir-93 cells were plated with or without DOX, and ALDH+ and ALDH2 cells were sorted at different times (12 hours, 1 day, 3 days, 8
days, 15 days) by Aldefluor assay. qRT-PCR was utilized to access the effects of mir-93 on mRNA expression of mesenchymal markers (Vimentin, N-
Cadherin and Twist), epithelial markers (E-Cadherin and Claudin), and TGFbR2. *p,0.05; Error bars represent mean 6 STDEV.
doi:10.1371/journal.pgen.1002751.g006
Figure 7. mir93 promotes MET in normal breast epithelial cells. A. Single cells were isolated from normal breast tissues and stained with
EpCAM-APC and CD49f-FITC for FACS sorting. After sorting, total RNA were isolated from different sorted groups (EpCAM+CD49f2, EpCAM+CD49f+,
EpCAM2CD49f+, EpCAM2CD49f2) and mir-93 expression were measured by qRT-PCR. p,0.05; Error bars represent mean 6 STDEV. B. Single cells
were isolated from normal breast tissues and infected with mir-93-expressing lentiviruses in suspension. After one week, mammospheres were
dissociated into single cells and plated in adherent culture in the absence (CTRL) or presence (DOX) of DOX for two weeks. Then, cells were
dissociated and stained with EpCAM-APC and CD49f-FITC for FACS analysis. C. MCF10A cells were cultured in the absence (CTRL) or presence (DOX) of
DOX for two weeks. Cells were then dissociated and stained with EpCAM-APC and CD49f-FITC for FACS analysis.
doi:10.1371/journal.pgen.1002751.g007
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The existence of alternative CSC states, associated with expression
of different protein markers has important implications for
understanding the plasticity of CSCs. For example, it has been
claimed that CSCs may be generated from non-CSC tumor
populations through induction of EMT [31]. However, the
existence of alternative CSC state suggests that the acquisition of
stem cell markers may reflect transition of CSC states rather than
generation of CSCs from non-CSC populations. In addition, the
existence of multiple stem cell states suggests the necessity of
developing of therapeutic strategies capable of effectively targeting
CSCs in all of these states.
Materials and Methods
Cell culture
Breast cancer cell line SUM159 and SUM149 have been
extensively characterized (http://www.asterand.com) [32].
HCC1954, MCF-7, MDA-MB-453 and MCF10A were purchased
from ATCC. The cell lines were grown using the recommended
culture conditions. Briefly, the culture medium for SUM159 and
SUM149 is Ham’s F-12 (Invitrogen) supplemented with 5% FBS,
5 ug/mL insulin, and 1 ug/mL hydrocortisone (both from Sigma,
St. Louis, MO). MCF7, MDA-MB-453 and HCC1954 cells were
maintained in RPMI1640 medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (ThermoFisher
Scientific, Pittsburgh, PA), 1% antibiotic-antimycotic (Invitrogen,
Carlsbad, CA), and 5 mg/ml insulin (Sigma-Aldrich, St Louis,
MO).
Dissociation of mammary tissue
100–200 g of normal breast tissue from reduction mammoplas-
ties was minced with scalpels, dissociated enzymatically, and single
cells were isolated as described previously [33,34]. The single cells
were utilized for FACS sorting or were cultured in suspension as
described previously [33,34]. Mammospheres were dissociated
into single cells enzymatically and mechanically, and then cultured
in regular cell culture plates [33,34].
Constructs and virus infection
For construction of the mir-93 sensor, miRNA-complementary
oligonucleotides were annealed and cloned into a Marx vector that
directs GFP expression. The mir-93 miRNA target sequence was
engineered into the 39 untranslated region (UTR) of the cDNA
encoding for the GFP fluorescent protein. Expression of this
construct in cells that express the mir-93 miRNA results in a RNAi
pathway-dependent degradation of GFP mRNA and thus no
green fluorescence. In contrast, in cells with repressed mir-93
miRNA, the GFP mRNA is not degraded and resulting in
expression of the fluorescent GFP. shRNA oligos for STAT3,
AKT3 or SOX4 were inserted to PlentiLox3.7-DsRed lentiviral
vector. A highly efficient lentiviral expression system (TRIPZ
lentivral vector;www.openbiosystems.com/RNAi) was used to
generate mir-93-expressing lentiviruses; and mirZIP-lentivector
(SBI, Mountain View, CA) was used to generate mir-93-
knockdown lentiviruses in UM Vector Core Facility. The cell
lines were infected with the lentiviruses as described previously
[34].
Aldefluor assay and flow cytometry
The Aldefluor kit (StemCell Technologies, Inc, Vancouver, BC,
Canada) was used to isolate cells with high ALDH enzymatic
activity as illustrated in the manufacturer’s instructions. Briefly,
single cells were suspended in buffer containing ALDH substrate –
BAAA (1 mmol/l per 16106 cells) and incubated at 37uC for
40 minutes. In each experiment, the specific ALDH inhibitor
diethylaminobenzaldehyde (DEAB) was used as negative control at
50 mmol/L. A FACStarPLUS (Becton Dickinson) was used for
FACS. Aldefluor fluorescence was excited at 488 nm and
fluorescence emission was detected using a standard fluorescein
isothiocyanate (FITC) 530/30 band pass filter. The sorting gates
Figure 8. A hypothetic model illustrating regulation of normal and malignant mammary stem cell states and fates by mir-93.
doi:10.1371/journal.pgen.1002751.g008
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were established based on negative controls. CD44/CD24 staining
was performed as previously described [14]. Briefly, cells were
stained with primary antibodies anti-CD44 labeled APC (dilution
1:10, BD Pharmingen), and anti-CD24 labeled FITC (dilution
1:10, BD Pharmingen). In all in vivo experiments, mouse cells were
eliminated by excluding H2Kd+ (mouse histocompatibility class I,
BD Pharmagen) cells during flow cytometry. 0.5 mg/ml 49,6-
diamidino-2-phenylindole (DAPI) (Sigma) was used to access cell
viability.
Cell cycle analysis
Cells (16106) were harvested and washed in cold PBS followed
by fixation in 70% alcohol for thirty minutes on ice. After washing
in cold PBS three times, cells were resuspended in 0.8 mL of PBS
solution with 40 mg of propidium iodide and 0.1 mg of RNase A
for thirty minutes at 37uC. Samples were analyzed for DNA
content using aFACSCalibur cytometer (Becton Dickinson, San
Jose, CA).
MTT assay
The effect of mir-93 on cell proliferation was measured using an
MTT assay. Briefly, 200–500 cells from Control and DOX-treated
groups were seeded in 96-well culture plates and were cultured in
the absence (CTRL) and presence (DOX) of DOX for 7 days.
Subsequently, 0.025 ml of MTT solution (5 mg/ml) was added to
each well, and the cells were incubated for 2 h. After centrifuga-
tion, the supernatant was removed from each well. The colored
formazan crystal produced from MTT was dissolved in 0.15 ml of
isopropanol with 4 mM HCl and 0.1% NP40, and the optical
density (OD) value was measured at 590 nm.
RNA extraction
Total RNA was isolated using RNeasy Micro Kit (Qiagen,
Valencia, CA), and total RNA with enriched miRNA was isolated
using miRNeasy mini Kit, according to the manufacturer’s
instructions.
Gene expression profiling with DNA microarrays
Gene expression analyses used Affymetrix U133 Plus 2.0 human
oligonucleotide microarrays containing over 47,000 transcripts
and variants including 38,500 well-characterized human genes.
Preparation of cRNA, hybridizations, washes and detection were
done as recommended by the supplier (http://www.affymetrix.
com/index.affx). Expression data were analyzed by the Robust-
Multichip Average method in R using Bioconductor and
associated packages [35].
Real-time quantitative PCR (qRT–PCR)
MiRNA expression level was measured utilizing TaqMan qRT-
PCR (Applied Biosystems, Carlsbad, CA). Single-stranded cDNA
was synthesized from 10 ng of miRNA enriched total RNA using
specific miRNA primers (TaqMan MiRNA Assay, PN 4427975,
Applied Biosystems) and the TaqMan MiRNA Reverse Tran-
scription Kit (PN 4366596, Applied Biosystems). Two ul of cDNA
was used as a template in a 20 ul PCR reaction. PCR products
were amplified using specific primers (TaqMan MiRNA Assay)
and the Taq-Man Universal PCR Master Mix (PN 4324018,
Applied Biosystems), and PCR was performed in a ABI PRISM
7900HT sequence detection system with 384-Well block module
and automation accessory (Applied Biosystems) by incubation at
50uC for two min and then 95uC for ten min followed by forty
amplification cycles (fifteen seconds of denaturation at 95uC and
one min of hybridization and elongation at 60uC). PCR reactions
for each sample were run in triplicate. The number of cycles
required for amplification to reach the threshold limit, the Ct-
value was used for quantification. RNU24 was used as an
endogenous control for miRNA data normalization, and TBP was
used as an endogenous control for other gene normalization. All
TaqMan miRNA assays used in this study were obtained from
Applied Biosystems.
Tumorigenicity in NOD/SCID mice
All mice were housed in the AAALAC-accredited specific
pathogen-free rodent facilities at the University of Michigan. Mice
were housed on sterilized, ventilated racks and supplied with
commercial chow and sterile water both previously autoclaved. All
experimentation involving live mice were conducted in accordance
with standard operating procedures approved by the University
Committee on the Use and Care of Animals at the University of
Michigan. Six-week old female NOD/SCID mice were purchased
from Jackson Laboratories (Bar Harbor, ME) and housed in SPF
microisolator cages in the animal facility of University of
Michigan. Tumorigenicity of 10,000 (Adjuvant setting) cells or
100,000 (Advanced setting) cells in the mamary fatpads of NOD/
SCID mice was accessed. Six mice were included in each cohort.
The animals were euthanized when the tumors were 1.0–1.5 cm
in diameter, in compliance with regulations for use of vertebrate
animal in research. A portion of each fat pad was fixed in formalin
and embedded in paraffin for histological analysis. Another
portion was analyzed by the ALDH or CD24/CD44 cytometric
staining.
Primary xenografts
Human breast tumors were obtained as biopsy cores or pieces of
tumors after surgery and implanted in humanized cleared fat pads
of NOD/SCID mice for establishing xenotransplants. The success
of xenotransplantation was approximately 20%, similar to
previous reports in the literature. Three xenotransplants were
used: an ER2PR2ERBB22 tumor at the 20th passage in animals
(MC1), an ER2PR2ERBB22 tumor at the 5th passage (UM1),
and an ER+PR+ERBB22 tumor at the 8th passage (UM2).
Intra-cardiac injection
All procedures were approved by the University Committee for
the Use and Care of Animals (UCUCA) of the University of
Michigan. The intracardiac injection was carried out according to
previously published methods [36]. Briefly, six-week-old NOD/
SCID mice were anesthetized with isoflurane gas (a 2%
isofluorane/air mixture) and injected in the left ventricle of the
heart with 100,000 cells in 100 ml of sterile Dulbecco’s PBS lacking
Ca2+ and Mg2+. For each of the cell lines (SUM159-luc,
HCC1954-luc), five animals were injected.
Bioluminescence imaging
Baseline bioluminescence was assessed before inoculation and
each week thereafter. Mice were anesthetized with isoflurane gas
and given a single i.p. dose of 150 mg/kg D-luciferin (Promega) in
PBS. For photon flux counting, we used a charge-coupled device
camera system (Xenogen) with a nose-cone isofluorane delivery
system and heated stage for maintaining body temperature.
Results were analyzed after six min of exposure using Living
Image software provided with the Xenogen IVIS imaging system.
Immunostaining
For ALDH1 staining, paraffin-embedded sections of breast
tumors from xenografts were deparaffinized in xylene and
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rehydrated in graded alcohol. Antigen enhancement was done by
incubating the sections in citrate buffer pH 6.0 (Dakocytomation,
Copenhagen, Denmark) as recommended. Slides were stained
using Peroxidase histostain-Plus Kit (Zymed) according to the
manufacturer’s protocol. ALDH1 antibody (BD biosciences) was
used at a 1:50 dilution. AEC (Zymed) was used as substrate for
peroxidase. Slides were counter-stained with hematoxylin and
coverslipped using glycerin. For E-Cadehrin, Vimentin, MCM7,
Ki67 and DAPI fluorescent staining, cells were fixed in ice-cold
methanol and permeablized with 0.15% triton X-100. E-Cadherin
antibody (Santa Cruz, 1:100 dilution), Vimentin antibody (Santa
Cruz, 1:200 dilution), MCM7 antibody (Cell signaling, 1:100
dilution), p21 antibody (Cell Signaling, 1:400 dilution) and Ki67
antibody (Dako, 1:150 dilution) were used and incubated for
1 hour at room temperature. PE and FITC labeled secondary
antibodies (Jackson Labs) were used at the dilution 1:200 and
incubated for twenty min. Nuclei were counterstained with DAPI/
antifade (INVITROGEN) and cover slipped. Sections were
examined with a Leica fluorescent microscope.
39 UTR luciferase reporter assay
The pMIR-REPORT luciferase reporter plasimds with the 39
UTR sequence of AKT3, SOX4, STAT3 or the control ACTB
were transfected into the cell lines using Fugene HD tansfection
reagent (Roche Applied Science) according to the manufacturer’s
instruction. After transfection, cells were dissociated and cultured
with or without DOX. Luciferase activity was assayed by luciferase
assay kit (Promega). Luciferase activities were measured after forty-
eight hrs utilizing a luminometer. The results were presented as
the luciferase activity of cells transfected with 39 UTR sequence of
AKT3, SOX4, or STAT3 normalized to cells transfected with the
luciferase activity of cells transfected with 39 UTR sequence of
ACTB.
Statistical analysis
Results are presented as the mean 6 standard deviation
(STDEV) for at least three repeated individual experiments for
each group using Microsoft Excel. Statistical differences were
determined by using ANOVA and student’s t-test for independent
samples. A p-value of less than 0.05 was considered statistically
significant.
Supporting Information
Figure S1 mir93 inhibits tumor growth and metastasis by
decreasing CSCs in HCC1954 cells. A. ALDH-positive cells from
HCC1954 cells shows lower mir93 expression level in comparison
to ALDH-negative cells by qRT-PCR. B. 16106 pTRIPZ-
HCC1954-mir93 cells were plated in T75 flasks and, after
overnight, the cells were treated with Vehicle control, DOX
(1 ug/ml), docetaxel (10 nM) or the combination for 3–7days.
Cells were utilized for Aldefluor assay and stained for Annexin V-
APC and DAPI for apoptosis assay. C. 100k pTRIPZ-HCC1954-
mir93 cells were injected into the 4th fatpads of NOD/SCID mice.
The treatment started as indicated by the red arrow. DOX alone
(1 mg/ml in drinking water), or docetaxel (10 mg/kg i.p. once
weekly) alone, or the combination inhibits SUM159 tumor growth
in vivo. D. Tumors from each group were collected. ALDH was
accessed by the Aldefluor assay on viable dissociated cells and by
ALDH1 immunohistochemistry on fixed sections. E. Serial
dilutions of cells obtained from these xenografts were implanted
in the 4th fatpads of secondary mice, which received no further
treatment. F. 10k pTRIPZ-HCC1954-mir93 cells were injected
into the 4th fatpads of NOD/SCID mice. The treatment started
immediately after injection as indicated by the red arrow and
stopped as indicated by the green arrow. G. 200k pTRIPZ-
HCC1954-mir93-luc cells in 100 ul of PBS were injected into the
left ventricle of NOD/SCID mice. The treatment started
immediately after injection as indicated by the red arrow and
stopped as indicated by the green arrow. Metastasis formation was
monitored using bioluminescence imaging. Quantification of the
normalized photon flux, measured at weekly intervals following
inoculation. H. Histologic confirmation, by H&E staining, of
metastasis in soft tissues resulting from mice with different
treatments in G. *p,0.05; Error bars represent mean 6 STDEV.
The colored ‘‘*’’ on the side of the tumor growth or metastasis
curve represents the tumor growth is significantly different
between Control group and the group with the same colored
curve.
(PDF)
Figure S2 mir-93 is induced in primary tumors with DOX. 100k
pTRIPZ-SUM159-mir-93 cells were injected into the 4th fatpads
of NOD/SCID mice. Different treatments were initiated (Vehicle
Control (Control), DOX alone (DOX), docetaxel alone, or the
combination). At the end of treatment, cells from Control and
DOX groups were isolated from the tumors and mir-93 expression
level was measured by qRT-PCR.
(PDF)
Figure S3 Induction of mir93 decreases both ALDH+ and
CD242CD44+ cells in the primary breast tumor xenografts. Cells
isolated from primary human breast xenografts UM2 (A), MC1 (B)
and UM1 (C) were sorted for ALDH+ and ALDH2 or
CD242CD44+ and the rest (CD242CD442, CD24+CD44+,
CD24+CD442). RNA was isolated from each group of sorted cells
and the expression level of mir-93 or RNU24 level was measured by
qRT-PCR. *p,0.05; Error bars represent mean 6 STDEV.
(PDF)
Figure S4 mir-93 expression in Sensor-GFP-positive and
Sensor-GFP-negative SUM159 cells. Mir-93-sensor-GFP
SUM159 cells were sorted for GFP-positive and GFP-negative
cells by flow cytometry and RNA was isolated from both group of
sorted cells and the expression level of mir-93 or RNU24 level was
measured by qRT-PCR. *p,0.05; Error bars represent mean 6
STDEV.
(PDF)
Figure S5 ALDH1A1 protein level in Sensor-GFP-positive and
Sensor-GFP-negative SUM159 cells. mir-93-sensor-GFP SUM159
cells were sorted for GFP-positive and GFP-negative cells by flow
cytometry. A portion of cells were utilized for western blot, and
some cells were cytospun down and stained with ALDH1A1 by
immunohistochemical staining. *p,0.05; Error bars represent
mean 6STDEV.
(PDF)
Figure S6 mir-93 induction reduces GFP in mir93-sensor-GFP-
SUM159 cells. mir93-sensor-GFP-SUM159 cells were infected
with pTRIPZ-mir93 lentivirus and grow in T75 flasks. DOX were
added to the culture medium in the DOX group. Images were
taken with fluorescence microscope.
(PDF)
Figure S7 16106 pTRIPZ-SUM149-mir93 cells were plated in
T75 flasks and, after overnight, the cells were treated with Vehicle
control or DOX (1 ug/ml) for 3–7 days. Induction of mir93
expression by DOX decreased the ALDH-positive population.
*p,0.05; Error bars represent mean 6 STDEV.
(PDF)
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Figure S8 Modulation of mir93 level in SUM159 cells altered
cell invasion in vitro and knockdown increases tumor growth in
vivo. SUM159 cells were infected with no virus (non-infection),
DsRed control lentivirus (SUM159-Neg-DsRed) or mirZip
antisense mir93 lentivirus (SUM159-mirZip93-DsRed). A. micro-
RNA RT-PCR demonstrated SUM159-mirZip93-DsRed reduced
mir93 expression by more than 90%. B. SUM159-non-infection,
SUM159-Neg-DsRed, SUM159-mirZip93-DsRed cells were
grown in T75 flasks and Aldefluor assay was utilized to measure
the percentage of ALDH+ cells. C. Serial dilutions of cells were
implanted in the 4th fatpads of NOD/SCID mice. SUM159-
mirZip93-DsRed cells initiated tumors sooner and accelerated
growth compared to equivalent number of control cells. D. Cells
were isolated from the tumors in C and Aldefluor assay was
utilized to measure the percentage of ALDH+ cells. E. Invasive
capacity was assessed by a Matrigel invasion assay using serum as
attractant. pTRIPZ-SUM159-mir93 cells are less invasive than the
control cells in vitro accesses at 27 hours. F. The invasion was
assessed by a Matrigel invasion assay using serum as attractant.
SUM159-mirZip93-DsRed cells are more invasive than the
control cells in vitro accesses at 27 hours. *p,0.05; Error bars
represent mean 6 STDEV. The colored ‘‘*’’ on the side of the
tumor growth curve represents the tumor growth is significantly
different between Control group and the group with the same
colored curve.
(PDF)
Figure S9 mir-93 inhibits tumor metastasis in SUM159 cells.
200k pTRIPZ-SUM159-mir-93-Luc cells in 100 ul of PBS were
injected into the left ventricle of NOD/SCID mice. Different
treatments were initiated (Vehicle Control (Control), DOX alone
(DOX), docetaxel alone, or the combination). At the end of
treatment, H&E staining and Pan-cytokeratin (AE1/AE3) staining
(in Brown) were performed to confirm the metastasis in bone and
soft tissues resulting from mice with different treatments.
(PDF)
Figure S10 mir93 inhibits tumor growth in primary human
breast xenografts MC1, UM2, and UM1. Cells isolated from
primary xenografts MC1 (A) or UM2 (B) or UM1 (C) were
transduced with the pTRIPZ-mir93 lentivirus in suspension. 10k
pTRIPZ-MC1-mir93 or pTRIPZ-UM2-mir93 cells were injected
into the 4th fatpads of NOD/SCID mice. The treatment started
right after injection as indicated by the red arrow. DOX alone,
docetaxel alone or the combination prevented tumor growth.
*p,0.05; Error bars represent mean 6 STDEV. The colored ‘‘*’’
on the side of the tumor growth curve represents the tumor growth
is significantly different between Control group and the group with
the same colored curve.
(PDF)
Figure S11 Endogenous mir93 expression levels parallel cell
differentiation state. ALDH+ population and ALDH2 population
were separated from SUM159 cells and HCC1954 cells.
CD242CD44+ population and the remaining cell populations
were separated from MCF7 cells. mir93 level was analyzed by
microRNA qRT-PCR. Among these three cell lines, mir93
expression level is highest in MCF7 cells and lowest in the
SM159 cells. In both SUM159 cells and HCC1954 cells, ALDH+
cells have lower mir93 expression compared to ALDH2 cells. In
contrast, CD242CD44+ in MCF7 cells showed no difference for
mir93 expression level in comparison to the bulk population.
*p,0.05; Error bars represent mean 6 STDEV.
(PDF)
Figure S12 mir93 promotes tumor growth by increasing CSCs
in MDA-MB-453 cells. A. 200k pTRIPZ-MDA-MB-453-mir93
cells were injected into the 4th fatpads of NOD/SCID mice.
Treatment was initiated as indicated by the red arrow. DOX
(1 mg/ml in drinking water) promoted MDA-MB-453 tumor
growth in vivo. B. Tumors from each group were collected.
Aldefluor assay was performed on dissociated cells. DOX
increased the ALDH+ populations in MDA-MB-453. C. Serial
dilutions of cells obtained from these xenografts were implanted in
the 4th fatpads of secondary mice, which received no further
treatment. Cells from DOX-treated tumors formed secondary
tumors at all dilutions (1k, 10k, 32k), whereas only higher numbers
of cells (32k) obtained from control xenografts were able to
generate tumors. *p,0.05; Error bars represent mean 6 STDEV.
(PDF)
Figure S13 mir93 promotes tumor growth by increasing CSCs
in T47D cells. A. 500k pTRIPZ-T47D-mir93 cells were injected
into the 4th fatpads of NOD/SCID mice. Treatment was initiated
as indicated by the red arrow. DOX (1 mg/ml in drinking water)
promoted T47D tumor growth in vivo. B. Tumors from each
group were collected. Aldefluor assay was performed on
dissociated cells. DOX increased the ALDH+ populations in
T47D. C. Serial dilutions of cells obtained from these xenografts
were implanted in the 4th fatpads of secondary mice, which
received no further treatment. Cells from DOX-treated tumors
formed secondary tumors at all dilutions (5k, 50k, 500k). *p,0.05;
Error bars represent mean 6 STDEV.
(PDF)
Figure S14 mir-93 is induced in primary tumors with DOX.
1000k pTRIPZ-MCF7-mir-93 cells were injected into the 4th
fatpads of NOD/SCID mice. Different treatments were initiated
(Vehicle Control (Control), DOX alone (DOX), docetaxel alone,
or the combination). At the end of treatment, cells from Control
and DOX groups were isolated from the tumors and mir-93
expression level was measured by qRT-PCR.
(PDF)
Figure S15 Validation of the 127 overlapped gene expression
with customerized StellArray PCR array plate in pTRIPZ-
SUM159-mir93.
(PDF)
Figure S16 Validation of the 127 overlapped gene expression
with customerized StellArray PCR array plate in pTRIPZ-
HCC1954-mir93.
(PDF)
Figure S17 Validation of the 127 overlapped gene expression
with customerized StellArray PCR array plate in pTRIPZ-MC1-
mir93.
(PDF)
Figure S18 Luciferase assay confirming mir93 targets. The
39UTR of AKT3, SOX4, and STAT3 pMIR-REPORT firefly
luciferase reporter plasmids with the wild-type 39UTR sequences
of AKT3, SOX4, or STAT3 were transiently transfected into
pTRIPZ-HCC1954-mir93 cells and an internal control ACTB
luciferase reporter was co-transfected for normalization. The cells
were treated with or without DOX. Luciferase activities were
measured after 48 hr. The relative luciferase activity is shown as
the ratio of (the results from the cells transfected by individual
reporter)/(the results from the cells transfected by the internal
control in the same cell group). *p,0.05; Error bars represent
mean 6 STDEV.
(PDF)
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Figure S19 Luciferase assay testing mir93 targets. The 39UTR
of AKT3, SOX4, and STAT3 pMIR-REPORT firefly luciferase
reporter plasmids with the wild-type 39UTR sequences of AKT3,
SOX4, or STAT3 were transiently transfected into pTRIPZ-
MCF7-mir93 (A) or pTRIPZ-MDA-MB-453-mir93 (B) cells and
an internal control ACTB luciferase reporter was co-transfected
for normalization. The cells were treated with or without DOX.
Luciferase activities were measured after 48 hr. The relative
luciferase activity is shown as the ratio of (the results from the cells
transfected by individual reporter)/(the results from the cells
transfected by the internal control in the same cell group). Error
bars represent mean 6 STDEV.
(PDF)
Figure S20 Knockdown of STAT3 (A), AKT3 (B) or SOX4 (C)
decreases ALDH+ cells in SUM159 cells. SUM159 cells were
transfected with PlentiLox3.7-shRNA-DsRed viruses and accessed
for the ALDH+ population by Aldeflour assay. *p,0.05; Error
bars represent mean 6 STDEV.
(PDF)
Figure S21 Validation of the 127 overlapped gene expression
with customerized StellArray PCR array plate in pTRIPZ-MCF7-
mir93.
(PDF)
Figure S22 The effects of mir93 on cell proliferation. Cell
proliferation was measured with the MTT assay. 200–500 cells
from Control and DOX-treated groups were seeded in 96-well
culture plates and were cultured in the absence (CTRL) and
presence (DOX) of DOX for 7days.Data represents means SEM,
n=5. *p,0.05; Error bars represent mean 6 STDEV.
(PDF)
Figure S23 Analysis of cell cycle for pTRIPZ-HCC1954-mir93
cells and pTRIPZ-MCF7-mir93cells. Cell cycle analysis of
pTRIPZ-HCC1954-mir93 cells and pTRIPZ-MCF7-mir93 cells
in the presence or absence of DOX. Propidium iodide staining
followed by flow cytometry was used to analyze cell cycle
distribution. Mir93 induced by DOX treatment resulted in a
decreased proportion of cells in the G0/G1 phase and an
increased proportion of cells in the S/G2/M phase for pTRIPZ-
HCC1954-mir93 cells. In contrast, DOX treatment has no effects
on the cell cycle for pTRIPZ-MCF7-mir93 cells.
(PDF)
Figure S24 MCM7 and Ki67 expression is increased in ALDH-
compared to ALDH+ SUM159 cells. ALDH + and 2 cells were
separated by Aldefluor assay and expression of Ki67 and MCM7
accessed by immunofluorescence. Ki67, Red; MCM7, Green;
DAPI, Blue. One representative sample from 3 independent
samples is shown.
(PDF)
Figure S25 mir93 expression induces MET in HCC1954 cells.
pTRIPZ-HCC1954-mir93 cells were plated in 2-well chamber
slides with (DOX) or without (CTRL) Doxycycline for 7 days. E-
Cadherin and Vimentin were stained with immunofluorescence
staining. E-Cadherin, Green; Vimentin, Red; DAPI, Blue. One
representative sample from 3 independent samples is shown.
(PDF)
Table S1 Downregualted probe set in ALDH+ population from
DOX vs. ALDH+ population from CTRL.
(PDF)
Table S2 mir93 direct targets in SUM159 cells. Overlap
between mir93 predicted targets from TargetScan 5.1 and
profiling data from DOX-treated cells (DOX) to non-DOX-
treated cells (CTRL) in the ALDH2 population (12 genes) or in
the ALDH+ population (352 genes). Known stem cell regulatory
genes highlighted in red. Genes underlined and bolded were
analyzed utilizing the luciferase reporter assay.
(PDF)
Table S3 Downregualted probe set in ALDH2 population from
DOX vs. ALDH2 population from CTRL.
(PDF)
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